MIMS Group Has Expanded International Operations

The healthcare data provider announced a global strategy to scale its clinical decision support platforms and services.

Updated on Sept. 28, 2026 in Healthcare

Isometric editorial illustration of medical research files and glass vials, representing the expansion of clinical data platforms. — MIMS Group is expanding its international operations and scaling its clinical decision support platforms, following the appointment of Sohil Goswami as CEO. AI Illustration. Upload story photo >

Live Poll

Do you trust that digitizing medical decision-making tools makes clinical workflows safer for healthcare professionals?

MIMS Group has announced an ambitious expansion of its product innovation and international reach, targeting new healthcare sectors and markets. This initiative follows the appointment of Sohil Goswami as Group CEO in January 2026.

Why it matters

By scaling its platforms, the company aims to better compete on a global stage while transitioning decades of established medical information into modern technology-driven solutions. The shift represents a strategic effort to leverage AI-enabled content to support healthcare providers across more diverse regions.

MIMS Group currently serves 17 global markets and reaches 2 million healthcare professional subscribers. The organization draws upon six decades of medical expertise to power its data platforms.

The players

MIMS Group

A Singapore-based company that provides medicines information and clinical decision support services to medical professionals.

Sohil Goswami

He was appointed as the Group CEO of MIMS Group in January 2026 to lead the company through its current phase of expansion.

The details

MIMS is transforming its long-standing repository of medical data into advanced technology platforms, such as the MIMS Pulse clinical decision support system. The firm is also broadening its medical communications business into the US and UK, alongside plans for new clinical modules and specialized categories like Drugs4Dent.

MIMS Group was established in 1963.
Sohil Goswami became Group CEO in January 2026.
MIMS announced its international growth strategy on September 28, 2026.

Market Landscape

MIMS Group's strategy follows the broader industry pattern of digitizing historical clinical knowledge to compete in global health tech markets. This move mirrors the ongoing digital transformation of legacy healthcare information services, positioning the firm against competitors by modernizing delivery models.

Healthcare professionals currently using the portal may see new clinical modules and expanded platform capabilities as the company rolls out its latest tech updates. Subscribers can expect these improvements to facilitate better decision-making through more integrated medicines data.

The takeaway

MIMS Group is pivoting from a traditional publisher to a technology-first company by integrating AI into its medical platforms. Providers should anticipate more interconnected clinical tools as the company scales its operations into new geographic and specialty markets.